in this issue
EnviroTech :: Biotech
Monsanto signs option agreement to support biologicals platform
8:16 AM MST | January 13, 2014 | Rebecca Coons
Tekmira Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has signed an option agreement under which Monsanto may obtain a license to use Tekmira's proprietary delivery technology. The transaction will support the application of Tekmira's proprietary delivery technology and related intellectual property (IP) for use in agriculture, Tekmira says. The company says the potential value of the transaction could reach up to $86.2 million following the successful completion of milestones. Tekmira expects to receive a...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee